The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors
Open accessAbstract
BACKGROUND: Hyperkalemia increases the risk of death and limits the use of inhibitors of the renin-angiotensin-aldosterone system (RAAS) in high-risk patients. We assessed the safety and efficacy of patiromer, a nonabsorbed potassium binder, in a multicenter, prospective trial. METHODS: Patients with chronic kidney disease who were receiving RAAS inhibitors and who had serum potassium levels of 5.1 to less than 6.5 mmol per liter received patiromer (at an initial dose of 4.2 g or 8.4 g twice a day) for 4 weeks (initial treatment phase); the primary efficacy end point was the mean change in the serum potassium level from baseline to week 4. Eligible patients at the end of week 4 (those with a baseline potassium level of 5.5 to <6.5 mmol per liter in whom the level decreased to 3.8 to <5.1 mmol per liter) entered an 8-week randomized withdrawal phase in which they were randomly assigned to continue patiromer or switch to placebo; the primary efficacy end point was the between-group difference in the median change in the serum potassium level over the first 4 weeks of that phase. RESULTS: In the initial treatment phase, among 237 patients receiving patiromer who had at least one potassium measurement at a scheduled visit after day 3, the mean (±SE) change in the serum potassium level was -1.01±0.03 mmol per liter (P<0.001). At week 4, 76% (95% confidence interval, 70 to 81) of the patients had reached the target potassium level (3.8 to <5.1 mmol per liter). Subsequently, 107 patients were randomly assigned to patiromer (55 patients) or placebo (52 patients) for the randomized withdrawal phase. The median increase in the potassium level from baseline of that phase was greater with placebo than with patiromer (P<0.001); a recurrence of hyperkalemia (potassium level, ≥5.5 mmol per liter) occurred in 60% of the patients in the placebo group as compared with 15% in the patiromer group through week 8 (P<0.001). Mild-to-moderate constipation was the most common adverse event (in 11% of the patients); hypokalemia occurred in 3%. CONCLUSIONS: In patients with chronic kidney disease who were receiving RAAS inhibitors and who had hyperkalemia, patiromer treatment was associated with a decrease in serum potassium levels and, as compared with placebo, a reduction in the recurrence of hyperkalemia. (Funded by Relypsa; OPAL-HK ClinicalTrials.gov number, NCT01810939.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs104 · Cited by 6,879
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Authors/Task Force Members:, Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehm236 · Cited by 2,384
(2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.03.003 · Cited by 1,245
Combined angiotensin inhibition for the treatment of diabetic nephropathy
Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303154 · Cited by 1,169
The Frequency of Hyperkalemia and Its Significance in Chronic Kidney Disease
Einhorn, L. M., Zhan, M., Hsu, V. D., Walker, L. D., Moen, M. F., Seliger, S. L., Weir, M. R., & Fink, J. C. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.132 · Cited by 646
Self-citationManaging hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system
Palmer, B. F. (2004) · New England Journal of Medicine · doi:10.1056/nejmra035279 · Cited by 640
Rank Methods for Combination of Independent Experiments in Analysis of Variance
Hodges, J. L., & Lehmann, E. L. (1962) · The Annals of Mathematical Statistics · doi:10.1214/aoms/1177704575 · Cited by 396
Cited by
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
Cheung, A. K., Chang, T. I., Cushman, W. C., Furth, S. L., Hou, F. F., Ix, J. H., Knoll, G. A., Muntner, P., Pecoits-Filho, R., Sarnak, M. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2020.11.003 · Cited by 1,452
Clase, C. M., Carrero, J.-J., Ellison, D. H., Grams, M. E., Hemmelgarn, B. R., Jardine, M. J., Kovesdy, C. P., Kline, G. A., Lindner, G., Obrador, G. T., et al. (2020) · Kidney International · doi:10.1016/j.kint.2019.09.018 · Cited by 498
Self-citation2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · Kardiologia Polska · doi:10.5603/kp.2016.0141 · Cited by 444
Bakris, G. L., Pitt, B., Weir, M. R., Freeman, M. W., Mayo, M. R., Garza, D., Stasiv, Y., Zawadzki, R., Berman, L., & Bushinsky, D. A. (2015) · JAMA · doi:10.1001/jama.2015.7446 · Cited by 441
Self-citationCollins, A. J., Pitt, B., Reaven, N., Funk, S., McGaughey, K., Wilson, D., & Bushinsky, D. A. (2017) · American Journal of Nephrology · doi:10.1159/000479802 · Cited by 403
Self-citationPalmer, S. C., Mavridis, D., Navarese, E., Craig, J. C., Tonelli, M., Salanti, G., Wiebe, N., Ruospo, M., Wheeler, D. C., & Strippoli, G. F. M. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62459-4 · Cited by 395
Agarwal, R., Rossignol, P., Romero, A., Garza, D., Mayo, M. R., Warren, S., Ma, J., White, W. B., & Williams, B. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32135-x · Cited by 368
Self-citationKovesdy, C. P., Matsushita, K., Sang, Y., Brunskill, N. J., Carrero, J. J., Chodick, G., Hasegawa, T., Heerspink, H. L., Hirayama, A., Landman, G. W. D., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy100 · Cited by 346
Cardiorenal Syndrome Revisited
Zannad, F., & Rossignol, P. (2018) · Circulation · doi:10.1161/circulationaha.117.028814 · Cited by 335
Galloway, C. D., Valys, A. V., Shreibati, J. B., Treiman, D. L., Petterson, F. L., Gundotra, V. P., Albert, D. E., Attia, Z. I., Carter, R. E., Asirvatham, S. J., et al. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.0640 · Cited by 318
Turakhia, M. P., Blankestijn, P. J., Carrero, J.-J., Clase, C. M., Deo, R., Herzog, C. A., Kasner, S. E., Passman, R. S., Pecoits-Filho, R., Reinecke, H., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy060 · Cited by 288
Self-citationPhysiology and pathophysiology of potassium homeostasis
Palmer, B. F., & Clegg, D. J. (2016) · Advances in Physiology Education · doi:10.1152/advan.00121.2016 · Cited by 280
Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis
Barrera-Chimal, J., Girerd, S., & Jaisser, F. (2019) · Kidney International · doi:10.1016/j.kint.2019.02.030 · Cited by 261
Hyperkalemia: pathophysiology, risk factors and consequences
Hunter, R. W., & Bailey, M. A. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz206 · Cited by 253
Currie, G., Taylor, A. H. M., Fujita, T., Ohtsu, H., Lindhardt, M., Rossing, P., Boesby, L., Edwards, N. C., Ferro, C. J., Townend, J. N., et al. (2016) · BMC Nephrology · doi:10.1186/s12882-016-0337-0 · Cited by 214
Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system
Nilsson, E., Gasparini, A., Ärnlöv, J., Xu, H., Henriksson, K. M., Coresh, J., Grams, M. E., & Carrero, J. J. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.07.035 · Cited by 211
Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study
Spinowitz, B. S., Fishbane, S., Pergola, P. E., Roger, S. D., Lerma, E. V., Butler, J., von Haehling, S., Adler, S. H., Zhao, J., Singh, B., et al. (2019) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12651018 · Cited by 198
Continuation of chronic heart failure therapies during heart failure hospitalization—a review
Singhania, G., Ejaz, A. A., McCullough, P. A., Kluger, A. Y., Balamuthusamy, S., Dass, B., Singhania, N., & Agarwal, A. (2019) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm.2019.03.562 · Cited by 20
Hyperkalemia in chronic kidney disease: a focus on potassium lowering pharmacotherapy
Sampani, E., Theodorakopoulou, M., Iatridi, F., & Sarafidis, P. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2245756 · Cited by 11
Metadata
- Authors
- Weir, M. R., Bakris, G. L., Bushinsky, D. A., Mayo, M. R., Garza, D., Stasiv, Y., Wittes, J., Christ-Schmidt, H., Berman, L., & Pitt, B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-01-15
- Volume
- 372
- Issue
- 3
- Pages
- 211-221
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2324948948
- Cited by
- 669
- References
- 27
- FWCI
- 42.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.